Mucosal immunization with recombinant adenoviral vectors expressing murine gammaherpesvirus-68 genes M2 and M3 can reduce latent viral load

Vaccine

Volumn 27, Issue 48, 2009, Pages 6723-6730

  Hoegh Petersen, Mette ^a   Thomsen, Allan R ^a   Christensen, Jan P ^a   Holst, Peter J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

CD8+ T cell; Herpesviruses; Immunity; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA IMMUNIZATION; FEMALE; HERPES VIRUS; HERPES VIRUS 68; IMMUNIZATION; IMMUNOGENICITY; LATENT VIRUS INFECTION; MOUSE; MUCOSA; NONHUMAN; PLASMID; PRIORITY JOURNAL; SPLENOMEGALY; T LYMPHOCYTE; VIRUS GENE; VIRUS INFECTION; VIRUS LOAD;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENES, VIRAL; HERPESVIRIDAE INFECTIONS; IMMUNITY, MUCOSAL; INJECTIONS, SUBCUTANEOUS; MICE; RHADINOVIRUS; SPLEEN; VIRAL LOAD; VIRAL PROTEINS; VIRAL VACCINES; VIRUS LATENCY;

EID: 70350571718     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.104     Document Type: Article

References (49)

1. Kutok J.L., and Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 1 (2006) 375-404
2. Ablashi D.V., Chatlynne L.G., Whitman Jr. J.E., and Cesarman E. Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin Microbiol Rev 15 3 (2002) 439-464
3. Doherty P.C., Christensen J.P., Belz G.T., Stevenson P.G., and Sangster M.Y. Dissecting the host response to a gamma-herpesvirus. Philos Trans R Soc Lond B Biol Sci 356 April (1408) (2001) 581-593
4. Tripp R.A., Hamilton-Easton A.M., Cardin R.D., Nguyen P., Behm F.G., Woodland D.L., et al. Pathogenesis of an infectious mononucleosis-like disease induced by a murine gamma-herpesvirus: role for a viral superantigen?. J Exp Med 185 May (9) (1997) 1641-1650
5. Flano E., Jia Q., Moore J., Woodland D.L., Sun R., and Blackman M.A. Early establishment of gamma-herpesvirus latency: implications for immune control. J Immunol 174 April (8) (2005) 4972-4978
6. Virgin H.W., Latreille P., Wamsley P., Hallsworth K., Weck K.E., Dal Canto A.J., et al. Complete sequence and genomic analysis of murine gammaherpesvirus 68. J Virol 71 8 (1997) 5894-5904
7. Hislop A.D., Annels N.E., Gudgeon N.H., Leese A.M., and Rickinson A.B. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 195 April (7) (2002) 893-905
8. Evans A.G., Moser J.M., Krug L.T., Pozharskaya V., Mora A.L., and Speck S.H. A gammaherpesvirus-secreted activator of Vbeta4+ CD8+ T cells regulates chronic infection and immunopathology. J Exp Med 205 March (3) (2008) 669-684
9. Flano E., Husain S.M., Sample J.T., Woodland D.L., and Blackman M.A. Latent murine gamma-herpesvirus infection is established in activated B cells, dendritic cells, and macrophages. J Immunol 165 July (2) (2000) 1074-1081
10. Stewart J.P., Usherwood E.J., Ross A., Dyson H., and Nash T. Lung epithelial cells are a major site of murine gammaherpesvirus persistence. J Exp Med 187 June (12) (1998) 1941-1951
11. Woodland D.L., Usherwood E.J., Liu L., Flano E., Kim I.J., and Blackman M.A. Vaccination against murine gamma-herpesvirus infection. Viral Immunol 14 3 (2001) 217-226
12. Usherwood E.J., Ward K.A., Blackman M.A., Stewart J.P., and Woodland D.L. Latent antigen vaccination in a model gammaherpesvirus infection. J Virol 75 17 (2001) 8283-8288
13. Obar J.J., Donovan D.C., Crist S.G., Silvia O., Stewart J.P., and Usherwood E.J. T-cell responses to the M3 immune evasion protein of murid gammaherpesvirus 68 are partially protective and induced with lytic antigen kinetics. J Virol 78 19 (2004) 10829-10832
14. Fowler P., and Efstathiou S. Vaccine potential of a murine gammaherpesvirus-68 mutant deficient for ORF73. J Gen Virol 85 Pt 3 (2004) 609-613
15. Tibbetts S.A., McClellan J.S., Gangappa S., Speck S.H., and Virgin H.W. Effective vaccination against long-term gammaherpesvirus latency. J Virol 77 4 (2003) 2522-2529
16. Tibbetts S.A., Suarez F., Steed A.L., Simmons J.A., and Virgin H.W. A gamma-herpesvirus deficient in replication establishes chronic infection in vivo and is impervious to restriction by adaptive immune cells. Virology 353 September (1) (2006) 210-219
17. Cush S.S., Anderson K.M., Ravneberg D.H., Weslow-Schmidt J.L., and Flano E. Memory generation and maintenance of CD8+ T cell function during viral persistence. J Immunol 179 July (1) (2007) 141-153
18. Maeda K., West K., Hayasaka D., Ennis F.A., and Terajima M. Recombinant adenovirus vector vaccine induces stronger cytotoxic T-cell responses than recombinant vaccinia virus vector, plasmid DNA, or a combination of these. Viral Immunol 18 4 (2005) 657-667
19. Santosuosso M., McCormick S., and Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 18 2 (2005) 283-291
20. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 January (6869) (2002) 331-335
21. Holst P.J., Sorensen M.R., Jensen C.M.M., Orskov C., Thomsen A.R., and Christensen J.P. MHC class II associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines. J Immunol (2008)
22. Cardin R.D., Brooks J.W., Sarawar S.R., and Doherty P.C. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. J Exp Med 184 September (3) (1996) 863-871
23. Becker T.C., Noel R.J., Coats W.S., Gómez-Foix A.M., Alam T., Gerard R.D., et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol (1994) 161-189
24. Christensen J.P., Kauffmann S.O., and Thomsen A.R. Deficient CD4+ T cell priming and regression of CD8+ T cell functionality in virus-infected mice lacking a normal B cell compartment. J Immunol 171 November (9) (2003) 4733-4741
25. Almeida J.R., Price D.A., Papagno L., Arkoub Z.A., Sauce D., Bornstein E., et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204 October (10) (2007) 2473-2485
26. Kristensen N.N., Christensen J.P., and Thomsen A.R. High numbers of IL-2-producing CD8+ T cells during viral infection: correlation with stable memory development. J Gen Virol 83 Pt 9 (2002) 2123-2133
27. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 February (7077) (2006) 682-687
28. Duvall M.G., Precopio M.L., Ambrozak D.A., Jaye A., McMichael A.J., Whittle H.C., et al. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 38 2 (2008) 350-363
29. Rehr M., Cahenzli J., Haas A., Price D.A., Gostick E., Huber M., et al. Emergence of polyfunctional CD8+ T cells after prolonged suppression of HIV replication by antiretroviral therapy. J Virol January (2008)
30. Seder R.A., Darrah P.A., and Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8 4 (2008) 247-258
31. Williams H., and Crawford D.H. Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood 107 February (3) (2006) 862-869
32. Viejo-Borbolla A., Ottinger M., and Schulz T.F. Human herpesvirus 8: biology and role in the pathogenesis of Kaposi's sarcoma and other AIDS-related malignancies. Curr HIV/AIDS Rep 1 1 (2004) 5-11
33. Xing Z., and Lichty B.D. Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis (Edinb) 86 3-4 (2006) 211-217
34. Bartholdy C., Stryhn A., Hansen N.J., Buus S., and Thomsen A.R. Incomplete effector/memory differentiation of antigen-primed CD8+ T cells in gene gun DNA-vaccinated mice. Eur J Immunol 33 7 (2003) 1941-1948
35. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107 June (12) (2006) 4781-4789
36. Wherry E.J., and Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 78 11 (2004) 5535-5545
37. Shin H., Wherry E.J., and CD8. T cell dysfunction during chronic viral infection. Curr Opin Immunol 19 4 (2007) 408-415
38. Obar J.J., Crist S.G., Gondek D.C., and Usherwood E.J. Different functional capacities of latent and lytic antigen-specific CD8 T cells in murine gammaherpesvirus infection. J Immunol 172 January (2) (2004) 1213-1219
39. Virgin H.W., Presti R.M., Li X.Y., Liu C., and Speck S.H. Three distinct regions of the murine gammaherpesvirus 68 genome are transcriptionally active in latently infected mice. J Virol 73 3 (1999) 2321-2332
40. Stevenson P.G., May J.S., Smith X.G., Marques S., Adler H., Koszinowski U.H., et al. K3-mediated evasion of CD8(+) T cells aids amplification of a latent gamma-herpesvirus. Nat Immunol 3 8 (2002) 733-740
41. Liang X., Shin Y.C., Means R.E., and Jung J.U. Inhibition of interferon-mediated antiviral activity by murine gammaherpesvirus 68 latency-associated M2 protein. J Virol 78 22 (2004) 12416-12427
42. Jensen K.K., Chen S.C., Hipkin R.W., Wiekowski M.T., Schwarz M.A., Chou C.C., et al. Disruption of CCL21-induced chemotaxis in vitro and in vivo by M3, a chemokine-binding protein encoded by murine gammaherpesvirus 68. J Virol 77 1 (2003) 624-630
43. Gillet L., May J.S., Colaco S., and Stevenson P.G. The murine gammaherpesvirus-68 gp150 acts as an immunogenic decoy to limit virion neutralization. PLoS ONE 2 1 (2007) e705
44. Hardy C.L., Flano E., Cardin R.D., Kim I.J., Nguyen P., King S., et al. Factors controlling levels of CD8+ T-cell lymphocytosis associated with murine gamma-herpesvirus infection. Viral Immunol 14 4 (2001) 391-402
45. Macallan D.C., Wallace D.L., Irvine A.J., Asquith B., Worth A., Ghattas H., et al. Rapid turnover of T cells in acute infectious mononucleosis. Eur J Immunol 33 10 (2003) 2655-2665
46. Bridgeman A., Stevenson P.G., Simas J.P., and Efstathiou S. A secreted chemokine binding protein encoded by murine gammaherpesvirus-68 is necessary for the establishment of a normal latent load. J Exp Med 194 August (3) (2001) 301-312
47. Lin S.W., Cun A.S., Harris-McCoy K., and Ertl H.C. Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut. Vaccine 25 March (12) (2007) 2187-2193
48. Stevenson P.G., May J.S., Smith X.G., Marques S., Adler H., Koszinowski U.H., et al. Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J Virol 74 15 (2000) 6741-6747
49. Tibbetts S.A., Loh J., van B.V., McClellan J.S., Jacoby M.A., Kapadia S.B., et al. Establishment and maintenance of gammaherpesvirus latency are independent of infective dose and route of infection. J Virol 77 13 (2003) 7696-7701